## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gravestock et al	Filed: Herewith				
Application No.: Not yet assigned	Attorney Docket No.: 100861-1P US				
Application No.: 10/536,686	Examiner: Not yet assigned				
Title: OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL					
AGENTS					

Mail Stop PCT Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant(s), wish to call the Examiner's attention to and make of record the references cited on the attached form(s) PTO-1449. All of the cited references were listed on the International Search Report, a copy of which is enclosed herewith for the convenience of the Examiner. Copies of the references are not being provided herewith because it is believed they were previously forwarded to the USPTO by the International Patent Bureau. Applicants are also enclosing a copy of the International Examination Report.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form.

Respectfully submitted,

Dated

Heidi Berven August 8, 2005

Reg. No.:

48,951

Phone No.:

1 781 839 4336

Enclosures:

Form 1449

International Search Report International Examination Report

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Complete if Known Substitute for Form 1449/PTO

Subsuit	TE IOI FO	111 177011 10				22	· · · · · · · · · · · · · · · · · · ·	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number 10/536,686				
			Filing Date		May 27, 2005			
			1	First Named Inventor		Michael Barry GRAVESTOCK		
			Art Unit		Not yet known			
				Examiner Name		Not yet known		
				Attorney Docket No. 100861-1P U		100861-1P US		
			U.S. PATE	ENT D	OCUMENTS			
	Cita	Document Number		N		o of Batastas as	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Examiner Initials*	Cite No.1	Number - Kind Code <sup>2 (if known)</sup>	Publication 0 MM-DD-YY				Figures Appear	
/N.C./	US1	5,698,574	December 16, 1997		Bayer Akt	iengesellschaft		
			FOREIGN PA	ATENT	DOCUMENT	'S		
Examiner	Cite	Foreign Patent Docume			Name of Patentee or Publication Date Applicant of Cited		Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials*	No.1			MM-DD-YYYY		Document	Figures Appear	T <sup>6</sup>
	AA	WO 03/022824			arch 20,	ASTRAZENECA		
/N.C./					03	AB, ASTRAZENCA		
INIOI						UK LIMITED		
	AB WO 01/94342			December		DONG A PHARM		
/N.C./					, 2001	CO LTD.,		
	AC	EP 0 352 781 A		January 31,		E.I. DU PONT		
/N.C./					90	DE NEMOURS		
		WO 04/049350		1	ne 10,	AND COMPANY ASTRAZENECA	ļ	ļ
/N.C./	AD	0 WO 04/048350			ne 10, 04	ASTRAZENECA AB,		
						ASTRAZENCA		
						UK LIMITED		
/NLO /	AE WO 04/048370			June 10,		ASTRAZENECA		
/N.C./					04	AB,		
						ASTRAZENCA		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup>Applicant is to place a check mark here if English language Translation is attached.

/Nizal Chandrakumar/

Date

Considered

05/03/2008

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO**: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.